BR112022005331A2 - Nova forma polimórfica de ácido (r)-2-[2-amino-3-(indol-3-il)propionilamino]-2-metilpropiônico e usos da mesma - Google Patents

Nova forma polimórfica de ácido (r)-2-[2-amino-3-(indol-3-il)propionilamino]-2-metilpropiônico e usos da mesma

Info

Publication number
BR112022005331A2
BR112022005331A2 BR112022005331A BR112022005331A BR112022005331A2 BR 112022005331 A2 BR112022005331 A2 BR 112022005331A2 BR 112022005331 A BR112022005331 A BR 112022005331A BR 112022005331 A BR112022005331 A BR 112022005331A BR 112022005331 A2 BR112022005331 A2 BR 112022005331A2
Authority
BR
Brazil
Prior art keywords
polymorphic form
propionylamino
indol
amino
methylpropionic acid
Prior art date
Application number
BR112022005331A
Other languages
English (en)
Inventor
Andras Szabo
Jozsef Repasi
Markus Henrich
Original Assignee
Galimedix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galimedix Therapeutics Inc filed Critical Galimedix Therapeutics Inc
Publication of BR112022005331A2 publication Critical patent/BR112022005331A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

a presente invenção se refere a uma nova forma polimórfica do composto ácido (r)-2-[2-amino-3-(indol-3-il)propionilamino]-2-metilpropiônico, um processo para a fabricação da nova forma polimórfica do composto e usos da mesma para a fabricação de outras formas polimórficas do composto. a invenção se refere ainda à composição compreendendo a nova forma polimórfica do composto e um carreador ou excipiente farmaceuticamente aceitável.
BR112022005331A 2019-09-23 2020-09-23 Nova forma polimórfica de ácido (r)-2-[2-amino-3-(indol-3-il)propionilamino]-2-metilpropiônico e usos da mesma BR112022005331A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962904339P 2019-09-23 2019-09-23
PCT/IB2020/058861 WO2021059142A1 (en) 2019-09-23 2020-09-23 Novel polymorph form of ( r)-2-[2-amino-3-(indol-3-yl)propionylamino]-2-methylpropionic acid and uses thereof

Publications (1)

Publication Number Publication Date
BR112022005331A2 true BR112022005331A2 (pt) 2022-06-14

Family

ID=75166037

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022005331A BR112022005331A2 (pt) 2019-09-23 2020-09-23 Nova forma polimórfica de ácido (r)-2-[2-amino-3-(indol-3-il)propionilamino]-2-metilpropiônico e usos da mesma

Country Status (8)

Country Link
US (1) US11891455B2 (pt)
EP (1) EP4034105B1 (pt)
CN (1) CN114466652A (pt)
BR (1) BR112022005331A2 (pt)
IL (1) IL291651A (pt)
MX (1) MX2022003533A (pt)
TW (1) TWI775154B (pt)
WO (1) WO2021059142A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022023734A2 (pt) * 2020-05-24 2023-02-07 Galimedix Therapeutics Inc Formas cristalinas de solvatos de derivados de triptofano, composições que as compreendeem e usos das mesmas

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7781396B2 (en) 2002-01-31 2010-08-24 Tel Aviv University Future Technology Development L.P. Peptides directed for diagnosis and treatment of amyloid-associated disease
AU2011281837A1 (en) * 2010-07-22 2013-03-14 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition containing a tryptophan derivative
EP2640737B1 (en) * 2010-11-15 2018-08-29 Ramot at Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
KR101244480B1 (ko) 2011-08-02 2013-03-18 부경대학교 산학협력단 전처리된 해조류 잔사의 추출물을 이용한 휘발성 지방산 제조 방법

Also Published As

Publication number Publication date
TW202126621A (zh) 2021-07-16
MX2022003533A (es) 2022-04-11
US20220389056A1 (en) 2022-12-08
EP4034105A4 (en) 2023-10-11
CN114466652A (zh) 2022-05-10
US11891455B2 (en) 2024-02-06
TWI775154B (zh) 2022-08-21
IL291651A (en) 2022-05-01
WO2021059142A1 (en) 2021-04-01
EP4034105A1 (en) 2022-08-03
EP4034105B1 (en) 2024-07-31

Similar Documents

Publication Publication Date Title
CO2022002637A2 (es) Proceso de fabricación de moduladores de cftr
BR112017023740A2 (pt) ?forma sólida de um composto, processo para a preparação de uma forma sólida, composição farmacêutica, método para o tratamento ou prevenção de doenças e utilização de uma forma sólida?
SA517390509B1 (ar) مركب مشتق ثلاثي الحلقات، وطريقة لتحضيره ، وتركيبة صيدلانية تشتمل عليه
CY1122046T1 (el) Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων
PE20201500A1 (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades
CO2017009614A2 (es) Compuestos bicíclicos de sulfonamida cetona
BRPI0611350B8 (pt) formulação, seus usos e seu processo de fabricação,e artigo de fabricação
BR112012027062A2 (pt) composto, processo para a preparação de um composto, método para prevenção e/ou tratamento de doenças e condições, e, composição farmacêutica
BR112015008717A2 (pt) composto, composição farmacêutica, método de tratar diabetes do tipo ii, uso do composto de fórmula (i), medicação para o tratamento de diabetes do tipo ii
CL2018002583A1 (es) Derivado de morfolina
BR112018073490A2 (pt) 6.7.beta-epóxidos esteroides como intermediários químicos
BR112022005331A2 (pt) Nova forma polimórfica de ácido (r)-2-[2-amino-3-(indol-3-il)propionilamino]-2-metilpropiônico e usos da mesma
BR112023001861A2 (pt) Composições e métodos para tratamento de doenças e distúrbios
JOP20210338A1 (ar) نظائر 3-(5-مثيل-3،1- ثيازول-2- يل)-n-{(1r)-1-[2-(تراي فلورومثيل) بيريميدين-5-يل] إثيل} بنزاميد
MX369556B (es) Procesos para la preparacion de derivados acidos de n-acetilgalactosamina (galnac).
BR112021024300A2 (pt) Formas de sais cristalinas de um inibidor de quinase
AR085291A1 (es) Metodos para sintetizar derivados del precursor z de molibdopterina
BR112016017816A8 (pt) derivados de etinila, seus usos, e composição farmacêutica
UY38304A (es) Dinucleótidos cíclicos como agonistas de sting y composiciones farmacéuticas que los contienen
BR112022016044A2 (pt) Processo para preparação de compostos artropodicidas de antranilamida
PH12019500119A1 (en) Ethynyl derivatives
BR112022008113A2 (pt) Formas sólidas de um modulador de receptor s1p
CY1118595T1 (el) Αρυλοαιθινυλο πυριμιδινες
BR112023005832A2 (pt) Forma cristalina de tegavivint, método de preparação e uso da mesma
BR112022011988A2 (pt) Processo para a preparação enzimática de um carboxilato de xilitol, carboxilato de xilitol e seu uso

Legal Events

Date Code Title Description
B25G Requested change of headquarter approved

Owner name: GALIMEDIX THERAPEUTICS INC. (US)